Compare MTRX & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MTRX | RCKT |
|---|---|---|
| Founded | 1984 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Engineering & Construction | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 275.6M | 239.3M |
| IPO Year | 1995 | 2014 |
| Metric | MTRX | RCKT |
|---|---|---|
| Price | $9.85 | $2.57 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 14 |
| Target Price | N/A | ★ $8.58 |
| AVG Volume (30 Days) | 474.9K | ★ 2.0M |
| Earning Date | 11-04-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 91.51 | 26.37 |
| EPS | N/A | ★ 0.66 |
| Revenue | ★ $873,632,000.00 | N/A |
| Revenue This Year | $6.70 | N/A |
| Revenue Next Year | $5.71 | $915.60 |
| P/E Ratio | ★ N/A | $3.75 |
| Revenue Growth | ★ 13.56 | N/A |
| 52 Week Low | $9.38 | $2.17 |
| 52 Week High | $15.97 | $5.45 |
| Indicator | MTRX | RCKT |
|---|---|---|
| Relative Strength Index (RSI) | 46.02 | 49.65 |
| Support Level | $9.67 | $2.17 |
| Resistance Level | $10.84 | $2.78 |
| Average True Range (ATR) | 0.34 | 0.17 |
| MACD | -0.03 | 0.06 |
| Stochastic Oscillator | 42.46 | 75.48 |
Matrix Service Co provides engineering, fabrication, construction, and maintenance services supporting critical energy infrastructure and industrial markets. Its reportable segments are Storage and Terminal Solutions, Utility and Power Infrastructure, and Process and Industrial Facilities, with Storage and Terminal Solutions generating the maximum revenue. This segment provides integrated EPC, repair, maintenance, and fabrication services for bulk liquid, cryogenic, and refrigerated storage and terminal facilities supporting traditional and emerging energy markets, including LNG, NGLs, petroleum products, chemicals, hydrogen, and ammonia, and manufactures specialty tank products. The majority of revenue is generated from the United States.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.